AWM
NVAX icon

Aberdeen Wealth Management’s Novavax NVAX Stock Holding History

Aberdeen Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.22K Buy
+660
New +$5.91K ﹤0.01% 355

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Aberdeen Wealth Management's NVAX Position: Q2 2026 in Review

Aberdeen Wealth Management opened a new position in Novavax (NVAX) in Q2 2026: 660 shares worth $6.22K. The stake represents ﹤0.01% of the portfolio and ranks #355 among its holdings.

266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Aberdeen Wealth Management held 660 shares of Novavax worth $6.22K as of Q2 2026.
  • Novavax was a new Aberdeen Wealth Management position in Q2 2026.
  • Novavax made up ﹤0.01% of Aberdeen Wealth Management's portfolio in Q2 2026, its #355 holding.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Aberdeen Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.